Gilead Sciences PT Raised to GBX 90 (IBT)
Equities researchers at BMO Capital Markets lifted their target price on shares of Gilead Sciences (LON:IBT) from GBX 85 ($1.38) to GBX 90 ($1.46) in a research report issued on Wednesday, AnalystRatings.Net reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would indicate a potential downside of 70.21% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Gilead Sciences from GBX 70 ($1.13) to GBX 80 ($1.29) in a research note to investors on Monday, October 28th. They now have an “outperform” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Gilead Sciences from GBX 70 ($1.13) to GBX 77 ($1.25) in a research note to investors on Monday, October 14th. They now have an “outperform” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Gilead Sciences from GBX 59 ($0.95) to GBX 67 ($1.08) in a research note to investors on Wednesday, September 18th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of GBX 76.59 ($1.24).
Gilead Sciences (LON:IBT) traded up 0.70% during mid-day trading on Wednesday, hitting GBX 302.103. The stock had a trading volume of 60,705 shares. Gilead Sciences has a 52 week low of GBX 1.94 and a 52 week high of GBX 3.2855. The stock has a 50-day moving average of GBX 2.89 and a 200-day moving average of GBX 2.67.
International Biotechnology Trust plc is an investment company. The investment objective of the Company is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.